Bausch Health Companies Inc. (NYSE:BHC) Receives Consensus Recommendation of “Hold” from Brokerages

Bausch Health Companies Inc. (NYSE:BHC) has been given an average rating of “Hold” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $7.75.

A number of brokerages recently commented on BHC. Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 1st. Jefferies Financial Group cut their target price on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Piper Sandler lowered shares of Bausch Health Companies from a “neutral” rating to an “underweight” rating and dropped their price target for the company from $9.00 to $3.00 in a research note on Friday, August 2nd. Scotiabank lowered their target price on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a report on Friday, August 2nd. Finally, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th.

Insiders Place Their Bets

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the sale, the executive vice president now directly owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. This trade represents a 2.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.12% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bausch Health Companies

Several large investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new position in Bausch Health Companies in the 2nd quarter valued at $35,000. MQS Management LLC purchased a new position in Bausch Health Companies during the second quarter worth about $71,000. Certuity LLC purchased a new position in Bausch Health Companies during the second quarter worth about $75,000. Bfsg LLC lifted its position in Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management purchased a new stake in Bausch Health Companies in the 2nd quarter valued at approximately $87,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Trading Down 0.8 %

Shares of NYSE BHC opened at $7.89 on Wednesday. The stock has a market capitalization of $2.90 billion, a PE ratio of -16.44 and a beta of 0.74. The stock has a fifty day simple moving average of $8.39 and a 200-day simple moving average of $7.11. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the company posted $1.03 EPS. The firm’s revenue was up 12.2% compared to the same quarter last year. On average, equities analysts predict that Bausch Health Companies will post 3.74 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.